Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

• Status: Active, not recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

"•Prospective, open label, randomized, multicenter study

• Patients treated with a new generation of Everolimus-eluting stents (Synergy®). After PTCA, patients are randomized to a group of DAPT for one year or a group of P2Y12 monotherapy after 3 months of DAPT. After 12 months of PTCA, evaluate major cardiovascular events and major bleeding events

• This study is to confirm after PTCA, DAPT for three months is not considered to be inferior to keeping DAPT for a year.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gangnam Severance Hospital
• Treatments: Aspirin; Clopidogrel; Everolimus; Ticagrelor

Criteria

Inclusion Criteria:

1. Age 19+

2. Patients treated with a new generation of Evelorimus-eluting stents (Synergy®)

3. Patients who understand the content of the subject description and voluntarily sign the subject

Exclusion Criteria:

1. Age 86+

2. Hemodynamically unstable patient

3. Severe hypersensitivity reactions to aspirin, clopidogrel, ticagrelor, everolimus, contrast agent

4. Patients at high risk of bleeding, anemia, thrombocytopenia

5. Patients requiring oral anticoagulants

6. Pregnant women or women of childbearing age

7. Life expectancy is less than one year

8. Patients receiving a potent CYP3A4 inhibitor (eg, ketoconazole, clarithromycin, napjodone, ritonavir, atazanavir)

9. Patients with a history of intracranial hemorrhage

10. Patients with moderate to severe hepatic impairment

11. Patients underwent coronary intervention with stenting within 1 year

12. Patients with left-main lesions requiring coronary intervention

13. Patients with chronic stricture lesions requiring treatment

14. Patients with in-stent restenosis in a lesion requiring treatment

15. Patients with bifurcation lesions requiring stenting in lateral branches

16. Patients with lesions requiring more than 3 stents